Indications
Nomi is specifically designed for the acute treatment of migraines in adults, whether with or without aura.
Pharmacology
Migraines are often attributed to localized cranial vasodilation or the release of sensory neuropeptides via nerve endings in the trigeminal system. Zolmitriptan, the active ingredient in Nomi, exerts its therapeutic effects by acting as an agonist at the 5-HT1B/1D receptors, leading to constriction of cranial vessels and inhibition of pro-inflammatory neuropeptide release.
Dosage & Administration
- Tablet: Begin with a 2.5 mg dose of Zolmitriptan, with a maximum single dose of 5 mg. If migraine symptoms persist after 2 hours or recur, a second dose may be taken after a minimum of 2 hours. The maximum daily dose should not exceed 10 mg within a 24-hour period.
- Nasal Spray: Administer one 5 mg dose of Zolmitriptan Nasal Spray for acute migraine relief, with the option of repeating the dose after 2 hours if needed. The maximum daily dose should not exceed 10 mg. Individual responses may vary, and the choice of dose and administration route should be determined on a case-by-case basis.
Contraindications
Avoid Nomi in patients with ischemic coronary artery disease, a history of stroke, recent use of a monoamine oxidase inhibitor, or known hypersensitivity to Zolmitriptan.
Side Effects
Common adverse reactions may include neck/throat/jaw pain or pressure, dizziness, paresthesia, asthenia, somnolence, warm/cold sensation, nausea, heaviness sensation, and dry mouth.
Pregnancy & Lactation
Pregnancy Category C. Use during pregnancy should be carefully considered based on the potential benefits versus risks. It is unclear whether Zolmitriptan is excreted in human milk, so nursing mothers should weigh the importance of the medication against potential risks to the infant.
Precautions & Warnings
Rare cases of serious cardiac adverse reactions, including acute myocardial infarction, have been reported shortly after administration. Patients may experience sensations of tightness, pain, and pressure in the chest, throat, neck, and jaw post-treatment with Nomi.
Use in Special Populations
Not recommended for pediatric use in patients under 18 years of age.
Therapeutic Class
Nomi belongs to the class of 5-HT Agonists, specifically formulated for migraine relief.
Storage Conditions
Store Nomi below 30°C, protected from light and moisture. Keep out of reach of children for safety.
Reviews
There are no reviews yet.